Azenta, Inc. (AZTA)
| Market Cap | 1.05B -14.5% |
| Revenue (ttm) | 596.48M +1.8% |
| Net Income | -173.34M |
| EPS | -3.78 |
| Shares Out | 46.09M |
| PE Ratio | n/a |
| Forward PE | 39.27 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,427,532 |
| Open | 22.44 |
| Previous Close | 22.49 |
| Day's Range | 22.42 - 23.45 |
| 52-Week Range | 15.93 - 41.73 |
| Beta | 1.43 |
| Analysts | Buy |
| Price Target | 26.20 (+14.51%) |
| Earnings Date | May 5, 2026 |
About AZTA
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sampl... [Read more]
Financial Performance
In fiscal year 2025, Azenta's revenue was $593.82 million, an increase of 3.55% compared to the previous year's $573.45 million. Losses were -$55.76 million, -66.18% less than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for AZTA stock is "Buy." The 12-month stock price target is $26.2, which is an increase of 14.51% from the latest price.
News
Azenta Publishes 2025 Environmental, Social, and Governance (ESG) Report
BURLINGTON, Mass., May 21, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the publication of its annual Environmental, Social, & Governance ("ESG") report, demonstrating continued pr...
Azenta, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Azenta, Inc. (NASDAQ: AZTA). The investigation focuses on Azenta's executiv...
Azenta Earnings Call Transcript: Q2 2026
Q2 organic revenue declined 3% year-over-year with margin pressures from lower North America volumes and execution gaps. Fiscal 2026 guidance was revised downward, but recurring revenue streams and European/Asian growth remain strong. Leadership and operational changes are underway to address challenges.
Azenta Earnings release: Q2 2026
Azenta released its Q2 2026 earnings on May 6, 2026, summarizing the period's financial results.
Azenta Slides: Q2 2026
Azenta has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on May 6, 2026.
Azenta Quarterly report: Q2 2026
Azenta has published its Q2 2026 quarterly earnings report on May 6, 2026.
Azenta Reports Second Quarter Results for Fiscal 2026, Ended March 31, 2026, Updates Full Year Fiscal 2026 Guidance, and Extends Long-Range Plan to 2029
FY'26 total reported revenue from continuing operations to range between approximately $603 to $621 million FY'26 organic revenue is now expected to range from down approximately 2% to up 1%, compared...
Azenta Announces Fiscal 2026 Second Quarter Conference Call and Webcast
BURLINGTON, Mass., April 29, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal second quarter 2026 earnings which ended on March 31, 2026, on Wednesday, May 6, 2026, before the mar...
Azenta Life Sciences Announces Leadership Transition to Accelerate Gene Synthesis Strategy and Multiomics Execution
BURLINGTON, Mass., April 7, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the appointment of Trey Martin as President of its Multiomics business, effective April 6, 2026.
Azenta price target lowered to $35 from $45 at Evercore ISI
Evercore ISI lowered the firm’s price target on Azenta (AZTA) to $35 from $45 and keeps an Outperform rating on the shares as part of the firm’s medical technology and…
Azenta price target lowered to $35 from $40 at Jefferies
Jefferies analyst Matthew Stanton lowered the firm’s price target on Azenta (AZTA) to $35 from $40 and keeps a Buy rating on the shares. The firm is updating its model…
Azenta Transcript: M&A announcement
The acquisition expands European presence, leverages automation synergies, and positions for scalable growth in life sciences. Minimal CapEx is required, with commercial investments driving future revenue and margin expansion. 2026 will be dilutive, but accretive from 2027.
Azenta Press release: M&A announcement
Azenta issued a press release on March 10, 2026, disclosing material business information to investors.
Azenta Slides: M&A announcement
Azenta has posted slides in relation to its latest quarterly earnings report, which was published on March 10, 2026.
Azenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository Capabilities
BURLINGTON, Mass., March 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA), a leading provider of life science solutions, today announced that its wholly owned subsidiary, Azenta UK Ltd, has acquire...
Azenta Transcript: 47th Annual Raymond James Institutional Investor Conference
The company is executing a turnaround with a focus on operational excellence, margin expansion, and commercial effectiveness. Key initiatives include decentralization, sales force transformation, and ABS-driven process improvements, with strong free cash flow and EBITDA growth targeted over the next three years.
Azenta Slides: 47th Annual Raymond James Institutional Investor Conference
Azenta has posted slides in relation to its latest quarterly earnings report, which was published on March 3, 2026.
Azenta to Participate in Raymond James 47th Annual Institutional Investor Conference
BURLINGTON, Mass., Feb. 24, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in Raymond James 47th Annual Institutional Investor Conference, on...
Azenta, Frontier Space announce strategic partnership
Azenta (AZTA) announced a strategic partnership with Frontier Space, a company in commercial space-based research systems, to conduct cutting-edge scientific experiments in space. This collaboration a...
Azenta Life Sciences and Frontier Space Announce Strategic Partnership to Advance Space-Based Life Sciences Research Infrastructure
BURLINGTON, Mass., Feb. 9, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced a strategic partnership with Frontier Space, a pioneer in commercial space-based research systems, to conduc...
Azenta price target lowered to $45 from $50 at Evercore ISI
Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Azenta (AZTA) to $45 from $50 and keeps an Outperform rating on the shares, calling shares “interesting” after the…
Azenta price target lowered to $30 from $39 at TD Cowen
TD Cowen lowered the firm’s price target on Azenta (AZTA) to $30 from $39 and keeps a Hold rating on the shares. The stock is down over 20% post earnings…
Azenta Earnings Call Transcript: Q1 2026
Q1 revenue was $149M, up 1% reported but down 1% organically, with margin pressures from quality issues and regional mix. FY2026 guidance for 3%-5% organic growth and 300 bps EBITDA margin expansion reaffirmed, with acceleration expected in the second half as investments and market conditions improve.
Azenta Quarterly report: Q1 2026
Azenta has published its Q1 2026 quarterly earnings report on February 4, 2026.
Azenta Earnings release: Q1 2026
Azenta released its Q1 2026 earnings on February 4, 2026, summarizing the period's financial results.